Literature DB >> 23406084

Recommendations on the potency labelling of factor VIII and factor IX concentrates.

A R Hubbard1, J Dodt, T Lee, K Mertens, R Seitz, A Srivastava, M Weinstein.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23406084     DOI： 10.1111/jth.12167

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  12 in total

1.  Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy.

Authors:  Steffen Rosen; Stefan Tiefenbacher; Mary Robinson; Mei Huang; Jaydeep Srimani; Donnie Mackenzie; Terri Christianson; K John Pasi; Savita Rangarajan; Emily Symington; Adam Giermasz; Glenn F Pierce; Benjamin Kim; Stephen J Zoog; Christian Vettermann
Journal:  Blood       Date:  2020-11-26       Impact factor: 22.113

2.  Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A.

Authors:  Pratima Chowdary; Manuel Carcao; Pål A Holme; Victor Jiménez-Yuste; Steven R Lentz; Judi Møss; Lone H Poulsen; Chunduo Shen; Alberto Tosetto; Allison Wheeler; Elena Santagostino
Journal:  Res Pract Thromb Haemost       Date:  2019-06-11

3.  Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence.

Authors:  Nina C Leksa; Maria M Aleman; Allison G Goodman; Deana Rabinovich; Robert Peters; Joe Salas
Journal:  J Thromb Haemost       Date:  2019-04-26       Impact factor: 5.824

4.  Estimation of Nuwiq® (simoctocog alfa) activity using one-stage and chromogenic assays-Results from an international comparative field study.

Authors:  Stefan Tiefenbacher; Manuela Albisetti; Peter Baker; Guenther Kappert; Steve Kitchen; Johanna A Kremer Hovinga; Claire Pouplard; Ute Scholz; Catherine Ternisien; Carin Borgvall; Tiago Vicente; Larisa Belyanskaya; Olaf Walter; Johannes Oldenburg
Journal:  Haemophilia       Date:  2019-05-20       Impact factor: 4.287

5.  A field study evaluating the activity of N8-GP in spiked plasma samples at clinical haemostasis laboratories.

Authors:  Stefan Tiefenbacher; Wan Hui Ong Clausen; Martin Hansen; Rasmus Lützhøft; Mirella Ezban
Journal:  Haemophilia       Date:  2019-07-11       Impact factor: 4.287

Review 6.  Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B.

Authors:  Richard A Marlar; Karin Strandberg; Midori Shima; Dorothy M Adcock
Journal:  Eur J Haematol       Date:  2019-11-13       Impact factor: 2.997

7.  Performance of factor IX extended half-life product measurements in external quality control assessment programs.

Authors:  Angelique Nederlof; Steve Kitchen; Piet Meijer; Marjon Cnossen; Nae Ali Pour; Geoffrey Kershaw; Ian Jennings; Isobel Walker; Moniek P M de Maat
Journal:  J Thromb Haemost       Date:  2020-06-10       Impact factor: 5.824

8.  Real-world assay variability between laboratories in monitoring of recombinant factor IX Fc fusion protein activity in plasma samples.

Authors:  Jurg M Sommer; Ali Sadeghi-Khomami; Christopher Barnowski; Margareta Wikén; Annemieke J Willemze
Journal:  Int J Lab Hematol       Date:  2020-03-23       Impact factor: 2.877

9.  Recombinant FIX Fc fusion protein activity assessment with the one-stage clotting assay: A multicenter, assessor-blinded, prospective study in Japan (J-Field Study).

Authors:  Katsuyuki Fukutake; Tomomi Kobayashi; Jurg M Sommer; Toshiyuki Hirakata
Journal:  Int J Lab Hematol       Date:  2019-12-10       Impact factor: 2.877

10.  Activity measurements of dalcinonacog alfa.

Authors:  Stella C Williams; Elaine Gray
Journal:  Haemophilia       Date:  2020-03-06       Impact factor: 4.287
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.